DD, I never thought that NWBO intended to market, manufacture, store, and distribute their products themselves. I see Advent doing that in the UK and perhaps elsewhere in Europe, and CRL eventually everywhere else. With the EDEN and trackable disposable cartridges they'll be able to track virtually every transaction, and they'll be in control as the EDEN's will be leased and maintained by them, but others will be doing the work and sharing the income for every batch of DCVax-L that's made.
Of course I've also previously mentioned that others could have EDEN's leased to them and their too the cassettes would track every new batch that was made. The EDEN is really the key to it all and once approved it can be utilized in the manner the company chooses.
Many here believe that in mass production the EDEN will cost less than $20,000 to make, if they're off by a factor of 5, IE $100,000, the sale of the first batch of DCVax-L should more than pay for it. At 50 or so batches a year it will be very profitable. I certainly can't say how much money NWBO will receive for each batch that's made, but in house they'll be doing very little work to get it done.
In the beginning I believe the demand will be far greater than the supply, so marketing will have more to do with scheduling the vaccine production than having to go into the field to sell the product. In time sufficient EDEN's and other equipment may be available to meet all demands, and a sales force may be desirable to increase production further, but by that time it will already be a blockbuster product many times over.
No doubt Advent will grow substantially, but CRL is already quite large, it will grow some, but should be able to easily handle what will be happening. I suspect that over time many CRL facilities will be making and handling DCVax-L rather than have everything come out of one of their many plants.
Of course this is my belief, it hasn't been contractually established. As for the Annual Report, it's loaded with statement on the problems the company could encounter, the SEC demands such language in every Annual Report, even from the most profitable corporations. In the case of production, etc. I don't believe they ever intended to do it all in house, but clearly if they did, it would be a major concern.
Let's get the UK approval, the EDEN approval, etc. then we can worry about all these other issues as we go for approval from all the other regulators.
Gary
News 
Market Data 
Discover 
